What Happened?

A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court ruled the previous week that the president could not use the International Emergency Economic Powers Act (IEEPA) for such duties, a decision that had initially sent markets higher. However, the administration invoked a different authority, the Trade Act of 1974, to impose a 15% global tariff for up to 150 days. The rapid reimposition of trade barriers creates significant uncertainty for companies across multiple sectors that depend on international supply chains and global trade. Investors are now weighing the potential impact of these new duties on corporate earnings and broader economic activity.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.

Among others, the following stocks were impacted:

• Surgical Equipment & Consumables - Specialty company Integra LifeSciences (NASDAQ: IART) fell 4.2%. Is now the time to buy Integra LifeSciences? Access our full analysis report here, it’s free.
• Medical Devices & Supplies - Specialty company Enovis (NYSE: ENOV) fell 3.1%. Is now the time to buy Enovis? Access our full analysis report here, it’s free.
• Senior Health, Home Health & Hospice company BrightSpring Health Services (NASDAQ: BTSG) fell 3.8%. Is now the time to buy BrightSpring Health Services? Access our full analysis report here, it’s free.
• Drug Development Inputs & Services company IQVIA (NYSE: IQV) fell 3.6%. Is now the time to buy IQVIA? Access our full analysis report here, it’s free.
• Drug Development Inputs & Services company Charles River Laboratories (NYSE: CRL) fell 5%. Is now the time to buy Charles River Laboratories? Access our full analysis report here, it’s free.

Zooming In On Charles River Laboratories (CRL)

Charles River Laboratories’s shares are quite volatile and have had 18 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The biggest move we wrote about over the last year was 10 months ago when the stock gained 17.3% on the news that the company reported strong first quarter 2025 results which significantly beat analysts' organic revenue and EPS estimates, and featured a raise to full-year EPS guidance. Zooming out, we think this was a solid print.

Charles River Laboratories is down 20.4% since the beginning of the year, and at $161.20 per share, it is trading 28.9% below its 52-week high of $226.77 from January 2026. Investors who bought $1,000 worth of Charles River Laboratories’s shares 5 years ago would now be looking at an investment worth $569.65.

While Wall Street chases Nvidia at all-time highs, an under-the-radar semiconductor supplier is dominating a critical AI component these giants can’t build without. Click here to access our full research report, it’s free.